Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. (CTNM), a clinical-stage biopharmaceutical company, reported a net loss of $60.0M for FY 2025 ended December 31, 2025, up 42% from $42.3M in FY 2024, driven by increased R&D expenses of $51.5M (34% YoY growth) from PIPE-791 Phase 2 IPF trial startup and chronic pain study, plus higher G&A of $16.5M. No revenue was recognized, as the $50.0M J&J upfront from PIPE-307 license was recorded in 2023. Loss from operations widened to $68.1M from $50.9M, offset by $8.2M interest income. Balance sheet strengthened with $276.6M total assets, including $75.6M cash equivalents and $187.3M marketable securities; stockholders' equity rose to $261.0M. Cash used in operations was $55.3M, funded by $112.7M financing including $93.0M follow-on offering and $19.0M ATM sales. Net cash increase of $53.7M supports runway through at least 12 months. Focus remains on PIPE-791 Phase 2 IPF (data 2028) and chronic pain topline Q2 2026, with PIPE-307 partnered to J&J.

Key Takeaways